We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Acer Shares Down on FDA's CRL for Genetic Disorder Treatment
Read MoreHide Full Article
Shares of Acer Therapeutics Inc. (ACER - Free Report) slumped more than 75% after it received a Complete Response Letter (CRL) from the FDA regarding its new drug application (NDA) for Edsivo (celiprolol) for the treatment of vascular Ehlers-Danlos Syndrome (vEDS). Ehlers-Danlos Syndrome (“EDS”) is an inherited disorder caused by mutations in the genes responsible for the structure, production, or processing of collagen.
In the CRL, the FDA has asked the company to conduct an adequate and well-controlled study to determine whether Edsivo reduces the risk of clinical events in patients with vEDS. Acer plans to request a meeting with the FDA to discuss its response. The company expects to respond to the FDA in the third quarter of 2019. The CRL implies a delay in the approval of Edsivo.
Edsivois a selective adrenergic modulator and is currently approved in the European Union for the treatment of hypertension and angina.
Edsivo has an Orphan Drug exclusivity designation in the United States for the vEDS indication.
The company also has other candidates in its pipeline. Its ACER-001 is a fully taste-masked, immediate release formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders (“UCD”) and Maple Syrup Urine Disease (“MSUD”). The company expects to submit an NDA for ACER-001 in UCD in the fourth quarter of 2019. The company also has osanetant in its pipeline, which is being evaluated for the treatment of various neuroendocrine disorders. An investigational new drug (“IND”) application for the drug is anticipated in the second half of 2019.
Cumberland’s earnings per share estimates have moved up from 7 cents to 46 cents for 2020 in the past 60 days. The company beat estimates in the trailing four quarters, the average being 137.17%.
Evotec’s earnings per share estimates have moved up from 90 cents to $1.03 for 2019 and from 97 cents to $1.37 for 2020 in the past 60 days.
Neos’ loss per share estimates have narrowed from 66 cents to 61 cents for 2019 in the past 60 days. The company outpaced estimates in two of the trailing four quarters, the average being 2.85%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market. Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Acer Shares Down on FDA's CRL for Genetic Disorder Treatment
Shares of Acer Therapeutics Inc. (ACER - Free Report) slumped more than 75% after it received a Complete Response Letter (CRL) from the FDA regarding its new drug application (NDA) for Edsivo (celiprolol) for the treatment of vascular Ehlers-Danlos Syndrome (vEDS). Ehlers-Danlos Syndrome (“EDS”) is an inherited disorder caused by mutations in the genes responsible for the structure, production, or processing of collagen.
In the CRL, the FDA has asked the company to conduct an adequate and well-controlled study to determine whether Edsivo reduces the risk of clinical events in patients with vEDS. Acer plans to request a meeting with the FDA to discuss its response. The company expects to respond to the FDA in the third quarter of 2019. The CRL implies a delay in the approval of Edsivo.
Edsivois a selective adrenergic modulator and is currently approved in the European Union for the treatment of hypertension and angina.
Edsivo has an Orphan Drug exclusivity designation in the United States for the vEDS indication.
The company also has other candidates in its pipeline. Its ACER-001 is a fully taste-masked, immediate release formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders (“UCD”) and Maple Syrup Urine Disease (“MSUD”). The company expects to submit an NDA for ACER-001 in UCD in the fourth quarter of 2019. The company also has osanetant in its pipeline, which is being evaluated for the treatment of various neuroendocrine disorders. An investigational new drug (“IND”) application for the drug is anticipated in the second half of 2019.
ACER Therapeutics, Inc. Price
Acer Therapeutics, Inc. price | Acer Therapeutics, Inc. Quote
Zacks Rank and Stocks to Consider
Acer currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks are Cumberland Pharmaceuticals Inc. (CPIX - Free Report) , Evotec AG and Neos Therapeutics Inc. , each carrying a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Cumberland’s earnings per share estimates have moved up from 7 cents to 46 cents for 2020 in the past 60 days. The company beat estimates in the trailing four quarters, the average being 137.17%.
Evotec’s earnings per share estimates have moved up from 90 cents to $1.03 for 2019 and from 97 cents to $1.37 for 2020 in the past 60 days.
Neos’ loss per share estimates have narrowed from 66 cents to 61 cents for 2019 in the past 60 days. The company outpaced estimates in two of the trailing four quarters, the average being 2.85%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market. Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>